Latest Mesoblast Ltd Sp ADR (MBLTY) Headlines
Post# of 4
Posted On: 03/10/2014 12:38:41 PM
Latest Mesoblast Ltd Sp ADR (MBLTY) Headlines
Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020
M2 - Mon Mar 10, 7:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gsw6jj/global_stem_cell) has announced the addition of the "Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020" report to their offering. The market is expected to reach revenue of $56.4 billion by 2020, growing at CAGR of 33.4% during 2013 to 2020 The study observed that the global umbilical cord blood stem cell market is forecasted to reach market value over $11.5 billion in 2014 from $ 6.5 billion in 2012. Developments and approvals for novel cord blood stem cells therapies is expected to drive the market growth. The storage service market was valued at $7.4 billion in 2013. Increase in prevalence rate of chronic diseases such as cancer, diabetes, blood disease, immune disease, metabolic disease etc. has increased the need of cost effective and efficient way of treatment. However, cord blood stem cells have the potential to treat these chronic diseases effectively. These stem cells have special property of higher cell count in lower blood volume. Collection of these stem cells is much easier than other stem cells and could be stored in specialized preservation facilities called as Cord Blood Stem Cell Banks.Cord blood stem cells market is in its emerging phase. Significant applications of stem cells in the treatment of various disorders will be commercialized very soon as most of them are in the last phase of clinical trials. Patents for collection techniques and therapeutics methods are approved by respective government of developed countries however patents for UCB stem cells are comparatively less in developing economies. According to lead analyst Debbie Shields, the geographic analysis shows that the North American market for cord blood stem cell would account for approx. 44% of total revenue generated by the cord blood market in 2013. However, much expected growth is to occur in Asia-Pacific regions during the forecast period, because of growing demand for chronic disease treatments and widely increasing awareness levels. This report study offers updated review about major market players present in this market such as researcher based pharmaceutical companies and therapeutics services companies. Key Market Segments Global Stem cell UCB market by storage - Public cord blood banks - Private cord blood banks - Public Vs. Private UCB banks Global Stem cell UCB market by Diseases - Cancer/ Oncology diseases - Acute Leukemia - Chronic Leukemia - High Risk Solid Tumors - Myelodysplastic Syndrome - Blood diseases - Aplastic Anemia - Beta Thalassemia - Sickle Cell disease - Immune Disorders - Leukocyte Adhesion Deficiency - Hystiocytic Disorders - Wiskott-Aldrich - Metabolic Disorders - Krabbe Disease - Hurler Syndrome - Sanfilippo Syndrome - Other diseases - Osteopetrosis - Hemophagoyticlymphohistiocytosis Global Stem cell UCB market by Technology - Stem Cell Transplant - Autologous transplant - Allogenic transplant - Transplant Medicine - Regenerative Medicine - Others - Cord Blood Banking - Blood Transfusion - Cell Based Genetics Companies Mentioned - Advanced Cell Technology Inc. (USA) - Athersys Inc. - California Stem Cell - Cytori Therapeutics Inc. - Geron Corporation - Mesoblast Limited - NeoStem Inc. - Opexa Therapeutics Inc. - Osiris Therapeutics - Pluristem Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/gs..._stem_cell
Former Roche Pharmaceuticals CEO Joins Mesoblast Board of Directors
GlobeNewswire - Wed Mar 05, 6:24PM CST
Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that William M. Burns, former Chief Executive Officer of Roche Pharmaceuticals, has been appointed a non-executive Director of the Mesoblast Board, effective immediately.
Mesoblast Reports Strong Half-Year Financial Results
GlobeNewswire - Tue Feb 25, 4:01PM CST
Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today provided its 2014 half-year financial results and operational highlights.
Bone Marrow Transplantation - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/f8glf8/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H1 2014" report to their offering. 'Bone Marrow Transplantation - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bone Marrow Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation. Scope - A snapshot of the global therapeutic scenario for Bone Marrow Transplantation. - A review of the Bone Marrow Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bone Marrow Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Bone Marrow Transplantation Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Bone Marrow Transplantation - Therapeutics Assessment Drug Profiles Allogeneic MPC For Bone Marrow Transplantation - Drug Profile melphalan - Drug Profile TM-400 - Drug Profile PLX-BMP - Drug Profile CBLB-612 - Drug Profile CBLB-612 - Drug Profile Perforin Inhibitor - Drug Profile R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Mesoblast Limited Cleveland BioLabs, Inc. Pluristem Therapeutics Inc. Spectrum Pharmaceuticals, Inc. TikoMed AB For more information visit http://www.researchandmarkets.com/research/f8...one_marrow About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
KEY EUROPEAN PATENT GRANTED FOR USE OF MESOBLAST'S MESENCHYMAL PRECURSOR CELLS IN CARDIAC AND VASCULAR CONDITIONS
GlobeNewswire - Wed Feb 19, 8:03PM CST
Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that it has been granted a key patent by the European Patent Office covering its proprietary adult Mesenchymal Precursor Cells (MPCs) for use in the treatment of cardiac and vascular conditions. European patent number EP1613335, entitled 'Perivascular Mesenchymal Precursor Cell Induced Blood Vessel Formation', provides Mesoblast with exclusive commercial rights in Europe initially through to 29 March 2024, with potential for extension based on duration of clinical development.
Cartilage Degeneration - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 17, 3:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/hzb6kb/cartilage) has announced the addition of the "Cartilage Degeneration - Pipeline Review, H2 2013" report to their offering. 'Cartilage Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cartilage Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cartilage Degeneration. Scope - A snapshot of the global therapeutic scenario for Cartilage Degeneration. - A review of the Cartilage Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cartilage Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Cartilage Degeneration Overview Therapeutics Development Clinical Stage Products Early Stage Products Cartilage Degeneration - Products under Development by Companies Cartilage Degeneration - Companies Involved in Therapeutics Development Cartilage Degeneration - Therapeutics Assessment Drug Profiles sprifermin - Drug Profile Chondrogen - Drug Profile MSB-CAR-001 - Drug Profile AOD-9604 - Drug Profile THR-166 - Drug Profile ST-03 - Drug Profile Cartilage Degeneration - Recent Pipeline Updates Appendix List of Tables List of Figures Companies Mentioned Sanofi Merck KGaA Mesoblast Limited Calzada Limited Thrasos, Inc. For more information visit http://www.researchandmarkets.com/research/hzb6kb/cartilage About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Akpabio - No Apology for Supporting Jonathan [interview]
All Africa Global Media - Thu Feb 13, 4:36AM CST
The Akwa Ibom State Governor, Godswill Akpabio, after paying a courtesy call on the National Chairman of the Peoples Democratic Party, Adamu Mu'azu, pledged his support to the new authority. Chuks Okocha presents excerpts of the session
Boardroom Radio Interview with Mesoblast Chief Executive
GlobeNewswire - Sun Feb 02, 7:07PM CST
Audio link - http://www.brrmedia.com/event/120127
POSITIVE SPINAL DISC REPAIR TRIAL RESULTS USING MESOBLAST ADULT STEM CELLS
GlobeNewswire - Wed Jan 29, 5:31PM CST
Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced positive 12 month outcome results from the 100-patient Phase 2 clinical trial of its proprietary allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells (MPCs) in patients with chronic moderate to severe discogenic low back pain.
Akingbola Challenges Lagos High Court's Jurisdiction
All Africa Global Media - Fri Jan 17, 1:23AM CST
Mr Erastus Akingbola, a former Managing Director of the defunct Intercontinental Bank Plc, on Thursday challenged the jurisdiction of a Lagos High Court to register a judgment against him by a London court.
2013 Report on the International Regenerative Medicine Markets
M2 - Mon Jan 13, 8:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/3gvqj4/regenerative) has announced the addition of the "2013 Report on the International Regenerative Medicine Markets" report to their offering. Astounding new advancements in the ability to repair or replace damaged human tissue and organ functions are being made. Whereas before, remedies for damaged tissue or organ functions due to congenital deformities, injuries, diseases or simple wear-and-tear relied upon either the body's ability to repair itself (or not), or a surgeon's skilled hands. Now, the area of regenerative medicine promises to revolutionize humanity's ability to remediate countless physical maladies that have perpetually afflicted humans and other animals. Compared to a select few life forms--like the starfish--man-made solutions for tissue repair and organ replacement haven't come close to nature's solutions. And where there once was no solution even offered by nature, researchers are now at the cusp of overcoming such limitations by "2013 Report on the International Regenerative Medicine Markets", enables the reader gain in-depth knowledge about ongoing tissue engineering and stem cell therapy research programs carried out in universities and other research centers. Moreover, this analysis profiles the leading companies developing regenerative medicine solutions. Key Topics Covered: 1. Overview 2. Regenerative Medicines: An Overview of Segments 3. Regenerative Medicine: The Next Evolution of Medical Treatment 4. Recent Advances in Regenerative Medicine and Stem Cell Research 5. Stem Cell Industry Highlights 6. Regenerative Medicines: A Brief Update from Selected Countries 7. Market Analysis for Regenerative Medicine Sector 8. Stem Cell Industry 9. Business Models and Requirements for a Successful Regenerative Medicine Industry 10. Company Profiles Companies Mentioned: - Aastrom Biosciences, Inc. - Advanced Cell Technology, Inc. (ACT) - Aldagen, Inc. - BeFutur Biotechnologies - Cardio BioSciences - CardioPolymers, Inc. - Develogen AG - Effector Cell Institute, Inc (ECI) - Epistem plc - FivePrime Therapeutics, Inc. - Forticell Bioscience, Inc. - Geron Corporation - Hydra Biosciences, Inc. - Intercytex Group plc - Japan Tissue Engineering, Co., Ltd. - Karocell Tissue Engineering AB - LifeCell - MaxCyte, Inc. - Mesoblast Ltd. - NanoCor's Products - Olympus Terumo Biomaterials Corporation - Pervasis Therapeutics, Inc. - RegeneRx - SyntheMed, Inc. - Thermogenesis Corp. - t cure GmbH For more information visit http://www.researchandmarkets.com/research/3g...generative
Osiris Announces Receipt of $15 Million Milestone Payment for Prochymal
Business Wire - Fri Dec 20, 7:30AM CST
Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products to treat conditions in orthopedic, sports medicine and wound care markets announced that it has received a $15 million milestone payment from Mesoblast for successful completion of the transfer of assets relating to the Prochymal business.
Global Pulmonary Fibrosis Pipeline Review Report - H2 2013 Edition Now Available
M2 - Tue Dec 17, 10:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/cqb72k/pulmonary) has announced the addition of the "Pulmonary Fibrosis - Pipeline Review, H2 2013" report to their offering. 'Pulmonary Fibrosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Pulmonary Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis. Scope - A snapshot of the global therapeutic scenario for Pulmonary Fibrosis. - A review of the Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Pulmonary Fibrosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Pulmonary Fibrosis Therapeutics Development - Eli Lilly and Company - Lpath, Inc. - Mesoblast Ltd - NicOx SA - Oncothyreon Inc - Pharmaxis Ltd. - Paloma Pharmaceuticals, Inc. - Digna Biotech, S.L. - Aquinox Pharmaceuticals Inc. - Angion Biomedica Corp. - Centocor Ortho Biotech, Inc. - Fibrotech Therapeutics Pty. Ltd. - FCB-Pharmicell Co.,Ltd. - Clarassance, Inc. Drug Profiles - Lpathomab - P-17 - AZX-100 - PX-866 - STNM-04 - P-529 - AQX-1125 - Btx-201 - GR-MD-02 - ICG-001 - CG-1011 - ANG-3298 - C-201 - Galectin-3 Inhibitors - SDP-051 - FT-011 - CT-140 - PDE-4A4 Inhibitors - NCX-466 - MC-1575 - Lungcellgram - CpG Oligonucleotides - PXS-5033-A For more information visit http://www.researchandmarkets.com/research/cqb72k/pulmonary
Market Research: Spinal Stenosis - Pipeline Review, H2 2013
M2 - Thu Dec 12, 2:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/2dgp4p/spinal_stenosis) has announced the addition of the "Spinal Stenosis - Pipeline Review, H2 2013" report to their offering. 'Spinal Stenosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Spinal Stenosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Spinal Stenosis. Scope - A snapshot of the global therapeutic scenario for Spinal Stenosis. - A review of the Spinal Stenosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Spinal Stenosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Dainippon Sumitomo Pharma Co., Ltd. Mesoblast Ltd LTT Bio-Pharma Co., Ltd. Sucampo Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/2d...l_stenosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Mesoblast Reports Positive Type 2 Diabetes Trial Results
GlobeNewswire - Tue Dec 03, 6:11PM CST
Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced top-line results from the Phase 2 trial of its proprietary Mesenchymal Precursor Cells (MPCs) in subjects with type 2 diabetes. The results of the trial support the safety and tolerability of a single intravenous infusion of MPCs in type 2 diabetes. Additionally, there was an improvement in glycemic control as evidenced by reduction in hemoglobin A1c (HbA1c).
New Japanese Regenerative Medicine Legislation and Commercial Opportunities for Stem Cell Products
GlobeNewswire - Sun Nov 24, 6:16PM CST
Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today gave an update on new legislation which provides a framework for accelerated approval of stem cell products in Japan, the world's second-largest mature healthcare market.
SCRIP Award to Mesoblast Recognizes Strategic Importance of '2013 Financing Deal of the Year'
GlobeNewswire - Fri Nov 22, 5:00AM CST
Regenerative medicine company Mesoblast Limited (ASX: MSB; OTC ADR: MBLTY) announced that it was today awarded the 'Financing Deal of the Year' at the 9th Annual 2013 SCRIP Awards in London, adjudicated by an independent panel of 15 judges who acknowledged corporate accomplishments in the pharmaceutical industry.
Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2013
M2 - Fri Nov 22, 3:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/l62htg/congestive_heart) has announced the addition of the "Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2013" report to their offering. 'Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Congestive Heart Failure (Heart Failure), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Congestive Heart Failure (Heart Failure). Scope - A snapshot of the global therapeutic scenario for Congestive Heart Failure (Heart Failure). - A review of the Congestive Heart Failure (Heart Failure) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Congestive Heart Failure (Heart Failure) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Aastrom Biosciences, Inc. Johnson & Johnson Amgen Inc. AstraZeneca PLC Athersys, Inc. GlaxoSmithKline plc Gilead Sciences, Inc. Merck & Co., Inc. Bioheart, Inc. Neurocrine Biosciences, Inc. Novartis AG Acorda Therapeutics, Inc. Dong-A Pharmaceutical Co., Ltd. Les Laboratoires Servier Bayer AG Celladon Corporation IntelGenx Technologies Corp. Mesoblast Ltd Palatin Technologies, Inc. Cardio3 BioSciences SA La Jolla Pharmaceutical Company and many more... For more information visit http://www.researchandmarkets.com/research/l6...tive_heart About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Mesoblast's Cell Therapy Strengthens Native Heart Function In Patients With End-Stage Heart Failure on Assisted Circulatory Support
GlobeNewswire - Mon Nov 18, 5:14PM CST
Patients with end-stage or New York Heart Association (NYHA) class IV heart failure who receive a surgically implanted left ventricular assist device (LVAD) heart pump to maintain circulation may obtain specific benefit to their native heart from a single dose of Mesoblast's proprietary mesenchymal precursor cells (MPCs) injected directly into their heart during surgery, a multicenter team of researchers within the United States National Institutes of Health (NIH)-funded Cardiothoracic Surgical Trials Network (CTSN), led by Icahn School of Medicine at Mount Sinai, New York, have found.
IMPROVED SURVIVAL IN CHILDREN WITH LIFE THREATENING GRAFT VERSUS HOST DISEASE REPORTED AFTER TREATMENT WITH MESOBLAST'S CELL THERAPY
GlobeNewswire - Wed Nov 13, 6:22PM CST
Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that a peer-reviewed article in the November 2013 issue of the scientific journal Biology of Blood and Marrow Transplantation has shown that use of its proprietary culture-expanded Mesenchymal Stem Cell (MSC) product, Prochymal(R), resulted in a significant survival benefit among responding pediatric bone marrow transplant recipients with refractory acute Graft versus Host Disease (GvHD). In 75 children with acute severe GvHD, 61% responded to Prochymal(R) and 76% of these were alive at day 100.
Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020
M2 - Mon Mar 10, 7:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gsw6jj/global_stem_cell) has announced the addition of the "Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020" report to their offering. The market is expected to reach revenue of $56.4 billion by 2020, growing at CAGR of 33.4% during 2013 to 2020 The study observed that the global umbilical cord blood stem cell market is forecasted to reach market value over $11.5 billion in 2014 from $ 6.5 billion in 2012. Developments and approvals for novel cord blood stem cells therapies is expected to drive the market growth. The storage service market was valued at $7.4 billion in 2013. Increase in prevalence rate of chronic diseases such as cancer, diabetes, blood disease, immune disease, metabolic disease etc. has increased the need of cost effective and efficient way of treatment. However, cord blood stem cells have the potential to treat these chronic diseases effectively. These stem cells have special property of higher cell count in lower blood volume. Collection of these stem cells is much easier than other stem cells and could be stored in specialized preservation facilities called as Cord Blood Stem Cell Banks.Cord blood stem cells market is in its emerging phase. Significant applications of stem cells in the treatment of various disorders will be commercialized very soon as most of them are in the last phase of clinical trials. Patents for collection techniques and therapeutics methods are approved by respective government of developed countries however patents for UCB stem cells are comparatively less in developing economies. According to lead analyst Debbie Shields, the geographic analysis shows that the North American market for cord blood stem cell would account for approx. 44% of total revenue generated by the cord blood market in 2013. However, much expected growth is to occur in Asia-Pacific regions during the forecast period, because of growing demand for chronic disease treatments and widely increasing awareness levels. This report study offers updated review about major market players present in this market such as researcher based pharmaceutical companies and therapeutics services companies. Key Market Segments Global Stem cell UCB market by storage - Public cord blood banks - Private cord blood banks - Public Vs. Private UCB banks Global Stem cell UCB market by Diseases - Cancer/ Oncology diseases - Acute Leukemia - Chronic Leukemia - High Risk Solid Tumors - Myelodysplastic Syndrome - Blood diseases - Aplastic Anemia - Beta Thalassemia - Sickle Cell disease - Immune Disorders - Leukocyte Adhesion Deficiency - Hystiocytic Disorders - Wiskott-Aldrich - Metabolic Disorders - Krabbe Disease - Hurler Syndrome - Sanfilippo Syndrome - Other diseases - Osteopetrosis - Hemophagoyticlymphohistiocytosis Global Stem cell UCB market by Technology - Stem Cell Transplant - Autologous transplant - Allogenic transplant - Transplant Medicine - Regenerative Medicine - Others - Cord Blood Banking - Blood Transfusion - Cell Based Genetics Companies Mentioned - Advanced Cell Technology Inc. (USA) - Athersys Inc. - California Stem Cell - Cytori Therapeutics Inc. - Geron Corporation - Mesoblast Limited - NeoStem Inc. - Opexa Therapeutics Inc. - Osiris Therapeutics - Pluristem Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/gs..._stem_cell
Former Roche Pharmaceuticals CEO Joins Mesoblast Board of Directors
GlobeNewswire - Wed Mar 05, 6:24PM CST
Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that William M. Burns, former Chief Executive Officer of Roche Pharmaceuticals, has been appointed a non-executive Director of the Mesoblast Board, effective immediately.
Mesoblast Reports Strong Half-Year Financial Results
GlobeNewswire - Tue Feb 25, 4:01PM CST
Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today provided its 2014 half-year financial results and operational highlights.
Bone Marrow Transplantation - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/f8glf8/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H1 2014" report to their offering. 'Bone Marrow Transplantation - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bone Marrow Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation. Scope - A snapshot of the global therapeutic scenario for Bone Marrow Transplantation. - A review of the Bone Marrow Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bone Marrow Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Bone Marrow Transplantation Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Bone Marrow Transplantation - Therapeutics Assessment Drug Profiles Allogeneic MPC For Bone Marrow Transplantation - Drug Profile melphalan - Drug Profile TM-400 - Drug Profile PLX-BMP - Drug Profile CBLB-612 - Drug Profile CBLB-612 - Drug Profile Perforin Inhibitor - Drug Profile R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Mesoblast Limited Cleveland BioLabs, Inc. Pluristem Therapeutics Inc. Spectrum Pharmaceuticals, Inc. TikoMed AB For more information visit http://www.researchandmarkets.com/research/f8...one_marrow About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
KEY EUROPEAN PATENT GRANTED FOR USE OF MESOBLAST'S MESENCHYMAL PRECURSOR CELLS IN CARDIAC AND VASCULAR CONDITIONS
GlobeNewswire - Wed Feb 19, 8:03PM CST
Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that it has been granted a key patent by the European Patent Office covering its proprietary adult Mesenchymal Precursor Cells (MPCs) for use in the treatment of cardiac and vascular conditions. European patent number EP1613335, entitled 'Perivascular Mesenchymal Precursor Cell Induced Blood Vessel Formation', provides Mesoblast with exclusive commercial rights in Europe initially through to 29 March 2024, with potential for extension based on duration of clinical development.
Cartilage Degeneration - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 17, 3:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/hzb6kb/cartilage) has announced the addition of the "Cartilage Degeneration - Pipeline Review, H2 2013" report to their offering. 'Cartilage Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cartilage Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cartilage Degeneration. Scope - A snapshot of the global therapeutic scenario for Cartilage Degeneration. - A review of the Cartilage Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cartilage Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Cartilage Degeneration Overview Therapeutics Development Clinical Stage Products Early Stage Products Cartilage Degeneration - Products under Development by Companies Cartilage Degeneration - Companies Involved in Therapeutics Development Cartilage Degeneration - Therapeutics Assessment Drug Profiles sprifermin - Drug Profile Chondrogen - Drug Profile MSB-CAR-001 - Drug Profile AOD-9604 - Drug Profile THR-166 - Drug Profile ST-03 - Drug Profile Cartilage Degeneration - Recent Pipeline Updates Appendix List of Tables List of Figures Companies Mentioned Sanofi Merck KGaA Mesoblast Limited Calzada Limited Thrasos, Inc. For more information visit http://www.researchandmarkets.com/research/hzb6kb/cartilage About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Akpabio - No Apology for Supporting Jonathan [interview]
All Africa Global Media - Thu Feb 13, 4:36AM CST
The Akwa Ibom State Governor, Godswill Akpabio, after paying a courtesy call on the National Chairman of the Peoples Democratic Party, Adamu Mu'azu, pledged his support to the new authority. Chuks Okocha presents excerpts of the session
Boardroom Radio Interview with Mesoblast Chief Executive
GlobeNewswire - Sun Feb 02, 7:07PM CST
Audio link - http://www.brrmedia.com/event/120127
POSITIVE SPINAL DISC REPAIR TRIAL RESULTS USING MESOBLAST ADULT STEM CELLS
GlobeNewswire - Wed Jan 29, 5:31PM CST
Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced positive 12 month outcome results from the 100-patient Phase 2 clinical trial of its proprietary allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells (MPCs) in patients with chronic moderate to severe discogenic low back pain.
Akingbola Challenges Lagos High Court's Jurisdiction
All Africa Global Media - Fri Jan 17, 1:23AM CST
Mr Erastus Akingbola, a former Managing Director of the defunct Intercontinental Bank Plc, on Thursday challenged the jurisdiction of a Lagos High Court to register a judgment against him by a London court.
2013 Report on the International Regenerative Medicine Markets
M2 - Mon Jan 13, 8:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/3gvqj4/regenerative) has announced the addition of the "2013 Report on the International Regenerative Medicine Markets" report to their offering. Astounding new advancements in the ability to repair or replace damaged human tissue and organ functions are being made. Whereas before, remedies for damaged tissue or organ functions due to congenital deformities, injuries, diseases or simple wear-and-tear relied upon either the body's ability to repair itself (or not), or a surgeon's skilled hands. Now, the area of regenerative medicine promises to revolutionize humanity's ability to remediate countless physical maladies that have perpetually afflicted humans and other animals. Compared to a select few life forms--like the starfish--man-made solutions for tissue repair and organ replacement haven't come close to nature's solutions. And where there once was no solution even offered by nature, researchers are now at the cusp of overcoming such limitations by "2013 Report on the International Regenerative Medicine Markets", enables the reader gain in-depth knowledge about ongoing tissue engineering and stem cell therapy research programs carried out in universities and other research centers. Moreover, this analysis profiles the leading companies developing regenerative medicine solutions. Key Topics Covered: 1. Overview 2. Regenerative Medicines: An Overview of Segments 3. Regenerative Medicine: The Next Evolution of Medical Treatment 4. Recent Advances in Regenerative Medicine and Stem Cell Research 5. Stem Cell Industry Highlights 6. Regenerative Medicines: A Brief Update from Selected Countries 7. Market Analysis for Regenerative Medicine Sector 8. Stem Cell Industry 9. Business Models and Requirements for a Successful Regenerative Medicine Industry 10. Company Profiles Companies Mentioned: - Aastrom Biosciences, Inc. - Advanced Cell Technology, Inc. (ACT) - Aldagen, Inc. - BeFutur Biotechnologies - Cardio BioSciences - CardioPolymers, Inc. - Develogen AG - Effector Cell Institute, Inc (ECI) - Epistem plc - FivePrime Therapeutics, Inc. - Forticell Bioscience, Inc. - Geron Corporation - Hydra Biosciences, Inc. - Intercytex Group plc - Japan Tissue Engineering, Co., Ltd. - Karocell Tissue Engineering AB - LifeCell - MaxCyte, Inc. - Mesoblast Ltd. - NanoCor's Products - Olympus Terumo Biomaterials Corporation - Pervasis Therapeutics, Inc. - RegeneRx - SyntheMed, Inc. - Thermogenesis Corp. - t cure GmbH For more information visit http://www.researchandmarkets.com/research/3g...generative
Osiris Announces Receipt of $15 Million Milestone Payment for Prochymal
Business Wire - Fri Dec 20, 7:30AM CST
Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products to treat conditions in orthopedic, sports medicine and wound care markets announced that it has received a $15 million milestone payment from Mesoblast for successful completion of the transfer of assets relating to the Prochymal business.
Global Pulmonary Fibrosis Pipeline Review Report - H2 2013 Edition Now Available
M2 - Tue Dec 17, 10:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/cqb72k/pulmonary) has announced the addition of the "Pulmonary Fibrosis - Pipeline Review, H2 2013" report to their offering. 'Pulmonary Fibrosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Pulmonary Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis. Scope - A snapshot of the global therapeutic scenario for Pulmonary Fibrosis. - A review of the Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Pulmonary Fibrosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Pulmonary Fibrosis Therapeutics Development - Eli Lilly and Company - Lpath, Inc. - Mesoblast Ltd - NicOx SA - Oncothyreon Inc - Pharmaxis Ltd. - Paloma Pharmaceuticals, Inc. - Digna Biotech, S.L. - Aquinox Pharmaceuticals Inc. - Angion Biomedica Corp. - Centocor Ortho Biotech, Inc. - Fibrotech Therapeutics Pty. Ltd. - FCB-Pharmicell Co.,Ltd. - Clarassance, Inc. Drug Profiles - Lpathomab - P-17 - AZX-100 - PX-866 - STNM-04 - P-529 - AQX-1125 - Btx-201 - GR-MD-02 - ICG-001 - CG-1011 - ANG-3298 - C-201 - Galectin-3 Inhibitors - SDP-051 - FT-011 - CT-140 - PDE-4A4 Inhibitors - NCX-466 - MC-1575 - Lungcellgram - CpG Oligonucleotides - PXS-5033-A For more information visit http://www.researchandmarkets.com/research/cqb72k/pulmonary
Market Research: Spinal Stenosis - Pipeline Review, H2 2013
M2 - Thu Dec 12, 2:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/2dgp4p/spinal_stenosis) has announced the addition of the "Spinal Stenosis - Pipeline Review, H2 2013" report to their offering. 'Spinal Stenosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Spinal Stenosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Spinal Stenosis. Scope - A snapshot of the global therapeutic scenario for Spinal Stenosis. - A review of the Spinal Stenosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Spinal Stenosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Dainippon Sumitomo Pharma Co., Ltd. Mesoblast Ltd LTT Bio-Pharma Co., Ltd. Sucampo Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/2d...l_stenosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Mesoblast Reports Positive Type 2 Diabetes Trial Results
GlobeNewswire - Tue Dec 03, 6:11PM CST
Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced top-line results from the Phase 2 trial of its proprietary Mesenchymal Precursor Cells (MPCs) in subjects with type 2 diabetes. The results of the trial support the safety and tolerability of a single intravenous infusion of MPCs in type 2 diabetes. Additionally, there was an improvement in glycemic control as evidenced by reduction in hemoglobin A1c (HbA1c).
New Japanese Regenerative Medicine Legislation and Commercial Opportunities for Stem Cell Products
GlobeNewswire - Sun Nov 24, 6:16PM CST
Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today gave an update on new legislation which provides a framework for accelerated approval of stem cell products in Japan, the world's second-largest mature healthcare market.
SCRIP Award to Mesoblast Recognizes Strategic Importance of '2013 Financing Deal of the Year'
GlobeNewswire - Fri Nov 22, 5:00AM CST
Regenerative medicine company Mesoblast Limited (ASX: MSB; OTC ADR: MBLTY) announced that it was today awarded the 'Financing Deal of the Year' at the 9th Annual 2013 SCRIP Awards in London, adjudicated by an independent panel of 15 judges who acknowledged corporate accomplishments in the pharmaceutical industry.
Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2013
M2 - Fri Nov 22, 3:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/l62htg/congestive_heart) has announced the addition of the "Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2013" report to their offering. 'Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Congestive Heart Failure (Heart Failure), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Congestive Heart Failure (Heart Failure). Scope - A snapshot of the global therapeutic scenario for Congestive Heart Failure (Heart Failure). - A review of the Congestive Heart Failure (Heart Failure) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Congestive Heart Failure (Heart Failure) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Aastrom Biosciences, Inc. Johnson & Johnson Amgen Inc. AstraZeneca PLC Athersys, Inc. GlaxoSmithKline plc Gilead Sciences, Inc. Merck & Co., Inc. Bioheart, Inc. Neurocrine Biosciences, Inc. Novartis AG Acorda Therapeutics, Inc. Dong-A Pharmaceutical Co., Ltd. Les Laboratoires Servier Bayer AG Celladon Corporation IntelGenx Technologies Corp. Mesoblast Ltd Palatin Technologies, Inc. Cardio3 BioSciences SA La Jolla Pharmaceutical Company and many more... For more information visit http://www.researchandmarkets.com/research/l6...tive_heart About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Mesoblast's Cell Therapy Strengthens Native Heart Function In Patients With End-Stage Heart Failure on Assisted Circulatory Support
GlobeNewswire - Mon Nov 18, 5:14PM CST
Patients with end-stage or New York Heart Association (NYHA) class IV heart failure who receive a surgically implanted left ventricular assist device (LVAD) heart pump to maintain circulation may obtain specific benefit to their native heart from a single dose of Mesoblast's proprietary mesenchymal precursor cells (MPCs) injected directly into their heart during surgery, a multicenter team of researchers within the United States National Institutes of Health (NIH)-funded Cardiothoracic Surgical Trials Network (CTSN), led by Icahn School of Medicine at Mount Sinai, New York, have found.
IMPROVED SURVIVAL IN CHILDREN WITH LIFE THREATENING GRAFT VERSUS HOST DISEASE REPORTED AFTER TREATMENT WITH MESOBLAST'S CELL THERAPY
GlobeNewswire - Wed Nov 13, 6:22PM CST
Regenerative medicine company Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that a peer-reviewed article in the November 2013 issue of the scientific journal Biology of Blood and Marrow Transplantation has shown that use of its proprietary culture-expanded Mesenchymal Stem Cell (MSC) product, Prochymal(R), resulted in a significant survival benefit among responding pediatric bone marrow transplant recipients with refractory acute Graft versus Host Disease (GvHD). In 75 children with acute severe GvHD, 61% responded to Prochymal(R) and 76% of these were alive at day 100.
(0)
(0)Mesoblast Ltd Sp Adr (MBLTY) Stock Research Links
Scroll down for more posts ▼